Literature DB >> 6205118

Does simian virus 5 infect humans?

K K Goswami, L S Lange, D N Mitchell, K R Cameron, W C Russell.   

Abstract

Simian virus 5 (SV5) isolates derived after co-cultivation of human bone marrow aspirates of multiple sclerosis (MS) patients were shown by immunoprecipitation, cross-neutralization and haemagglutination inhibition techniques to be similar antigenically but not identical to the prototype strain. Analyses of human sera (MS and control) showed that about 20% contained neutralizing antibodies to SV5 and immunoprecipitated the specific SV5 HN polypeptide. A competition assay using a specific SV5 monoclonal antibody confirmed that a human serum containing such neutralizing activity also blocked a specific SV5 epitope whereas another human serum with demonstrable antibodies to the related human parainfluenza virus type 2 did not block this epitope. These tests therefore suggested that SV5 can infect humans. However, there was no indication, on the basis of these tests, of any aetiological relationship of the SV5 infection to the induction of MS.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6205118     DOI: 10.1099/0022-1317-65-8-1295

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  19 in total

1.  The actin cytoskeleton inhibits pore expansion during PIV5 fusion protein-promoted cell-cell fusion.

Authors:  Mark A Wurth; Rachel M Schowalter; Everett Clinton Smith; Carole L Moncman; Rebecca Ellis Dutch; Richard O McCann
Journal:  Virology       Date:  2010-08-15       Impact factor: 3.616

2.  Structure of the paramyxovirus parainfluenza virus 5 nucleoprotein-RNA complex.

Authors:  Maher Alayyoubi; George P Leser; Christopher A Kors; Robert A Lamb
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-23       Impact factor: 11.205

3.  Characterization of human parainfluenza virus type 3 persistent infection in cell culture.

Authors:  A Moscona; M S Galinski
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

4.  Multiple amino acid substitutions in the HN protein of the paramyxovirus, SV5, are selected for in monoclonal antibody resistant mutants.

Authors:  D U Baty; R E Randall
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

5.  A respiratory syncytial virus (RSV) vaccine based on parainfluenza virus 5 (PIV5).

Authors:  Shannon I Phan; Zhenhai Chen; Pei Xu; Zhuo Li; Xiudan Gao; Stephanie L Foster; Michael N Teng; Ralph A Tripp; Kaori Sakamoto; Biao He
Journal:  Vaccine       Date:  2014-04-08       Impact factor: 3.641

6.  A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.

Authors:  Dai Wang; Shannon Phan; Daniel J DiStefano; Michael P Citron; Cheryl L Callahan; Lani Indrawati; Sheri A Dubey; Gwendolyn J Heidecker; Dhanasekaran Govindarajan; Xiaoping Liang; Biao He; Amy S Espeseth
Journal:  J Virol       Date:  2017-05-12       Impact factor: 5.103

7.  Sendai virus and simian virus 5 block activation of interferon-responsive genes: importance for virus pathogenesis.

Authors:  L Didcock; D F Young; S Goodbourn; R E Randall
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

8.  A novel CD8-independent high-avidity cytotoxic T-lymphocyte response directed against an epitope in the phosphoprotein of the paramyxovirus simian virus 5.

Authors:  P M Gray; G D Parks; M A Alexander-Miller
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  Solid matrix-antibody-antigen complexes induce antigen-specific CD8+ cells that clear a persistent paramyxovirus infection.

Authors:  R E Randall; D F Young
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

10.  Clearance of a persistent paramyxovirus infection is mediated by cellular immune responses but not by serum-neutralizing antibody.

Authors:  D F Young; R E Randall; J A Hoyle; B E Souberbielle
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.